SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin inks pact with Eli Lilly for anti-diabetic drugs

01 Aug 2011 Evaluate

Lupin has inked a pact with Eli Lilly to promote and distribute the US firm's anti-diabetic drugs, including Huminsulin RTM, in India and Nepal. Lupin and Eli Lilly have entered into a strategic collaboration to promote and distribute Lilly's Huminsulin range of products, including Huminsulin RTM, Huminsulin NPHTM, Huminsulin 50/50TM, Huminsulin 30/70TM and Humapen Ergo II.

According to IMS June 2011 data, the total Indian insulin market is valued at Rs 975 crore and Huminsulin is the second biggest brand portfolio in the same. Lupin will market and distribute the entire range of Huminsulin brand. The total sales of the brand is close to Rs 125 crore.crackcrack

Lupin Share Price

2246.00 0.35 (0.02%)
12-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1845.90
Dr. Reddys Lab 1270.10
Cipla 1292.00
Zydus Lifesciences 930.75
Lupin 2246.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×